Startup Funding News
Explore funding rounds, the companies behind them and the investors taking part.
- Rounds
- 4,642 Jan 1 – Oct 26, 2026
- Disclosed funding
- $339.4B 3645 disclosed amounts
- Median round
- $14.8M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| V Builds technologies for spatial biology and multi-omics innovation | $48M | Series A | Biotech | United States | Investors | |
 AbbelightCompany profile Microscopy and nanoscopy systems combining chemistry, optics and analysis for life-science researchers. Microscopy and nanoscopy systems combining chemistry, optics and analysis for life-science researchers. | Undisclosed | Series B | Biotech | France | Investors | |
| F Medical imaging data management and analysis platform | $27.5M | Undisclosed | Healthtech | United States | Investors | |
| ET Enodia TherapeuticsCompany profile Develops small-molecule therapies for targeted protein degradation at the point of synthesis Develops small-molecule therapies for targeted protein degradation at the point of synthesis | €20.7M | Seed | Biotech | France | Investors | |
 EpiBiologicsCompany profile Develops bispecific antibodies for targeted degradation of extracellular proteins. Develops bispecific antibodies for targeted degradation of extracellular proteins. | $107M | Series B | Biotech | United States | Investors | |
 BrightHeartCompany profile BrightHeart develops AI software for prenatal ultrasound and fetal-heart screening. BrightHeart develops AI software for prenatal ultrasound and fetal-heart screening. | €11M | Series A | AI | France | Investors | |
| PD Perceptive DiscoveryCompany profile Provides preclinical and translational solutions for oncology and radiopharmaceutical programs Provides preclinical and translational solutions for oncology and radiopharmaceutical programs | $15M | StrategicUndisclosed | Biotech | United Kingdom | Investors | |
| PM Parabilis MedicinesCompany profile Develops medicines targeting historically undruggable protein targets in cancer Develops medicines targeting historically undruggable protein targets in cancer | $305M | Series FSeries C+ | Biotech | United States | Investors Alderline GroupARCH Venture Partners +21Catalio Capital ManagementCormorant Asset ManagementFarallon Capital ManagementFidelity Management & Research CompanyForesite CapitalFrazier Life SciencesGeneral CatalystGV (Google Ventures)HBM HealthcareInvusJanus Henderson InvestorsMarshall WaceMilky Way InvestmentsNextech InvestRA Capital ManagementRock Springs CapitalSamsara BioCapitalSixty Degree CapitalSoleus CapitalT. Rowe Price AssociatesvenBio Partners | |
| A Develops specialized AI systems for regulated industries | $70M | Series B | AI | United States | Investors | |
| U Provides a global clearing system for tokenised deposits and stablecoins | Undisclosed | StrategicUndisclosed | Fintech | United Kingdom | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1Y Combinator (YC)
Tractian, Blacksmith, Databuddy Analytics
160rounds5led - 2Andreessen Horowitz (a16z)
ASI, Eka Robotics, Town
111rounds21led - 3General Catalyst
Tractian, Legora, Different
100rounds12led - 4Lightspeed
Warp Sciences, Different, Zenzap
80rounds8led - 5Sequoia Capital
Warhound, Whop, Blacksmith
71rounds13led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.
Browse rounds by topic
Geography
Featured selections
Nordic Foodtech Fund II pairs early capital with scientific expertise
An EIF pledge of up to €30m supports a fund targeting €80m for science-led agrifood companies.
Read the research →